PCM
VYNE icon

Penserra Capital Management’s VYNE Therapeutics VYNE Stock Holding History

Penserra Capital Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-66
Closed -$1K – 1567
2021
Q3 		$1K Buy
66
+1
+2% +$39 ﹤0.01% 1444
2021
Q2 		$4K Hold
65
– – ﹤0.01% 1323
2021
Q1 		$7K Buy
65
+12
+23% +$1.74K ﹤0.01% 1065
2020
Q4 		$6K Buy
+53
New +$6.66K ﹤0.01% 978

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Penserra Capital Management's VYNE Position: Q4 2021 in Review

Penserra Capital Management sold out of VYNE Therapeutics (VYNE) in Q4 2021, closing a stake of 66 shares — an estimated $1K sold.

Penserra Capital Management first reported a position in VYNE in Q4 2020 and held it in 4 quarters. The position peaked at $7K in Q1 2021. 54 funds tracked by Wall St. Rank hold VYNE as of Q4 2021.

  • Penserra Capital Management reported no remaining VYNE Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 66 VYNE Therapeutics shares in Q4 2021, an estimated $1K.
  • Penserra Capital Management first reported a position in VYNE Therapeutics in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's VYNE Therapeutics position peaked at $7K in Q1 2021.
  • 54 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.